生物科技公司Replimune Group, Inc. (NASDAQ: REPL )市值为8.92亿美元，该公司周一宣布任命Michael Goller加入董事会。根据 InvestingPro 分析，该公司保持强劲的流动性，流动比率为11.4倍，但在过去十二个月中面临盈利能力挑战，EBITDA为负2.36亿美元。Goller的加入使董事会成员从九人增至十人。

With the FDA granting a priority review to the BLA, a decision from the regulatory body is expected on July 22, 2025. Shares of REPL were up 16.9% on Jan. 21 following the announcement of the news ...

Founded in 2015, REPL Sports is a leading sports organisation dedicated to promoting healthier lifestyles among today’s youth ...

小摩：维持Replimune Group(REPL.US)评级，由增持调整至增持评级, 目标价由16.00美元调整至18.00美元。 Replimune（REPL.US）公司简介：Replimune Group Inc是一家 ...

Shares of NASDAQ REPL opened at $12.29 on Thursday. The firm’s 50-day moving average is $12.78 and its two-hundred day moving average is $12.04. The company has a market capitalization of $946. ...

Shares of REPL stock opened at $14.10 on Thursday. The company has a market cap of $964.72 million, a price-to-earnings ratio of -4.62 and a beta of 1.30. Replimune Group has a 52 week low of $4. ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

WOBURN, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...